KRAS and neoplasm: For instance, in colorectal cancer, the inactivation of the APC tumor suppressor gene, activation of the KRAS oncogene, and subsequent loss of TP53 create a combined effect of functional gains and losses in achieving a pro-tumor genetic landscape [[42], [43], [44], [45]].